Drug Trial Radar · NCT06025578
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,057
Planned (sponsor's estimate)
Start
Oct 25, 2023
Primary completion
Dec 27, 2027
Study completion Dec 27, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Conditions
- Progressive Pulmonary Fibrosis
Interventions
BMS-986278Drug
Specified dose on specified days
BMS-986278 PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants that experience spontaneous syncopal eventsTime frame: At approximately 4 weeks
- Absolute change from baseline in forced vital capacity (FVC) measured in mLTime frame: At Week 52
Locations
459 sites in 35 countries. Site status is shown where the registry gives one.
Local Institution - 0046
Birmingham, Alabama
Local Institution - 0314
Phoenix, Arizona
Local Institution - 0336
La Jolla, California
Local Institution - 0212
Los Angeles, California
Local Institution - 0019
Los Angeles, California
Local Institution - 0535
Newport Beach, California
Local Institution - 0366
Orange, California
Local Institution - 0341
Sacramento, California
Local Institution - 0015
San Francisco, California
Local Institution - 0352
Stanford, California
Local Institution - 0321
Aurora, Colorado
Local Institution - 0376
Denver, Colorado
Local Institution - 0211
New Haven, Connecticut
Local Institution - 0418
Stamford, Connecticut
Local Institution - 0067
Newark, Delaware
Local Institution - 0354
Washington D.C., District of Columbia
Local Institution - 0195
Brandon, Florida
Local Institution - 0380
Celebration, Florida
Local Institution - 0013
Clearwater, Florida
Local Institution - 0396
DeBary, Florida
Local Institution - 0036
Gainesville, Florida
Local Institution - 0193
Gainesville, Florida
Local Institution - 0073
Loxahatchee Groves, Florida
Local Institution - 0220
Ocala, Florida
Local Institution - 0452
Pensacola, Florida
Local Institution - 0389
St. Petersburg, Florida
Local Institution - 0316
Tampa, Florida
Local Institution - 0070
Atlanta, Georgia
Local Institution - 0368
Dublin, Georgia
Local Institution - 0435
Chicago, Illinois
Local Institution - 0023
Chicago, Illinois
Local Institution - 0040
Evanston, Illinois
Local Institution - 0082
Maywood, Illinois
Local Institution - 0080
Iowa City, Iowa
Local Institution - 0049
Kansas City, Kansas
Local Institution - 0045
Louisville, Kentucky
Local Institution - 0361
Louisville, Kentucky
Local Institution - 0305
Baltimore, Maryland
Local Institution - 0033
Towson, Maryland
Local Institution - 0404
Boston, Massachusetts
Showing 40 of 459 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.